Belzutifan is Well-Tolerated and Might Be an Addition to a Standard of Care
Katriina Jalkanen, from Helsinki University Hospital, discusses the LITESPARK study results on belzutifan, a new drug for renal cell carcinoma (RCC), at ESMO 2024. Key findings include statistically significant progression-free survival (PFS) with belzutifan compared to everolimus and a higher response rate (22.7% vs. 3.5%). In addition belzutifan is well-tolerated and could be used in future treatment combinations or earlier lines an Addition to a Standard of Care.
